- Home
- MBC vs MIRM Comparison
MBC vs MIRM Comparison
Compare MBC & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBC
- MIRM
- Stock Information
- Founded
- MBC 1954
- MIRM 2018
- Country
- MBC United States
- MIRM United States
- Employees
- MBC N/A
- MIRM N/A
- Industry
- MBC Agricultural Chemicals
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- MBC Industrials
- MIRM Health Care
- Exchange
- MBC Nasdaq
- MIRM Nasdaq
- Market Cap
- MBC 2.3B
- MIRM 2.5B
- IPO Year
- MBC N/A
- MIRM 2019
- Fundamental
- Price
- MBC $14.30
- MIRM $52.45
- Analyst Decision
- MBC Strong Buy
- MIRM Strong Buy
- Analyst Count
- MBC 1
- MIRM 11
- Target Price
- MBC $23.00
- MIRM $57.00
- AVG Volume (30 Days)
- MBC 966.8K
- MIRM 504.4K
- Earning Date
- MBC 02-18-2025
- MIRM 02-26-2025
- Dividend Yield
- MBC N/A
- MIRM N/A
- EPS Growth
- MBC N/A
- MIRM N/A
- EPS
- MBC 0.96
- MIRM N/A
- Revenue
- MBC $2,700,400,000.00
- MIRM $307,028,000.00
- Revenue This Year
- MBC $2.41
- MIRM $83.04
- Revenue Next Year
- MBC $7.56
- MIRM $27.22
- P/E Ratio
- MBC $15.07
- MIRM N/A
- Revenue Growth
- MBC N/A
- MIRM 112.14
- 52 Week Low
- MBC $13.90
- MIRM $23.14
- 52 Week High
- MBC $20.67
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- MBC 25.84
- MIRM 64.07
- Support Level
- MBC $14.03
- MIRM $51.02
- Resistance Level
- MBC $16.95
- MIRM $53.76
- Average True Range (ATR)
- MBC 0.58
- MIRM 2.04
- MACD
- MBC -0.34
- MIRM 0.03
- Stochastic Oscillator
- MBC 7.48
- MIRM 73.31
About MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers, and builders.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.